Description: Omega Therapeutics, Inc., a biotechnology company, develops genomic medicines to cure diseases. The company focuses on precision tuning to activate the human genome's native capacity to treat and cure diseases. It engages in designing, engineering, and manufacturing Epigenomic Controllers to target the GenomStats for the cell types of interest, with the ability to downregulate or upregulate genomic activity for therapeutic effect. Omega Therapeutics, Inc. was formerly known as VL42, Inc. and changed its name to Omega Therapeutics, Inc. in July 2017. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.
Home Page: omegatherapeutics.com
OMGA Technical Analysis
20 Acorn Park Drive
Cambridge,
MA
02140
United States
Phone:
617 949 4360
Officers
| Name | Title |
|---|---|
| Dr. Noubar B. Afeyan Ph.D. | Co-Founder & Chairman |
| Mr. Mahesh Karande | Pres, CEO & Board Director |
| Dr. Thomas McCauley | Chief Scientific Officer |
| Mr. Joshua Reed M.B.A. | Chief Financial Officer |
| Dr. Sivakesava Sakhamuri Ph.D. | Sr. VP and Head of Technical Operations & Quality |
| Ms. Ling Zeng Esq., J.D. | Chief Legal & Admin. Officer and Sec. |
| Mr. Kevin McManus | Chief HR Officer |
| Ms. Barbara Y. Chan | Sr. VP of Fin. |
| Mr. Charles O'Donnell Ph.D. | VP and Head of Computational Genomics & Data Sciences |
| Dr. Yan Moore M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2829 |
| Price-to-Sales TTM: | 197.7721 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 79 |